Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in ...

Very high Lp(a) also correlated with higher risks of ischemic stroke and cardiovascular mortality in the Women’s Health Study ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Lipoprotein(a) levels, which are largely determined by genetics, appear to fluctuate over time, particularly in individuals with moderately elevated concentrations, a UK Biobank analysis shows. People ...

Please provide your email address to receive an email when new articles are posted on . Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular ...

Please provide your email address to receive an email when new articles are posted on . Lipoprotein(a) should be measured in all people at least once. “Evaluation and management of Lp(a) is actionable ...

For many, a 12-inch platter of vinyl, spinning 33 1/3 revolutions per minute, exemplifies how they first listened to music. But long before rock and roll, soul, and other popular music styles were ...